Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market : Industrial Analysis, Growth, Segmentation and Forecast-2019-2027

The Global Market for Lysosomal Acid Lipase (LAL) Deficiency Treatment was valued $xx Mn in 2019 and is expected to reach $xx Mn in 2027, at a CAGR of xx%.

Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Introduction and Overview

Lysosomal Acid Lipase deficiency (LAL-D) is an inherited, ultra-rare, autosomal recessive Lysosomal storage disease. The deficiency is caused due to mutations in the LAL gene. These alterations in the gene, prevent it from breaking down the cholesteryl esters and triglycerides. As a result, there is accumulation of lipids in the liver, spleen and the walls of blood vessels. The deficiency of LAL enzyme causes the autosomal recessive disorders- Wolman Disease (WD) and Cholesteryl Ester Storage Disease (CESD). FDA approval for Sebelipase (Kanuma) - the first drug for treating LAL-D boosted the market growth. The drug was developed using the Enzyme Replacement Therapy (ERT) which enhanced the growth of ERT segment. At present, kanuma is the only drug approved for the treatment of Wolman and CESD. The rising cases of liver transplant is in turn elevating the LAL-D market. However, disease diagnosis remains poor, as majority of people are unaware and remain undiagnosed. There is a strong need of awareness about timely diagnosis of the disease. In addition to this, inadequacy for therapeutics and high treatment costs are major restraints for market growth. The report covers the detailed analysis of global market for Lysosomal Acid Lipase (LAL) deficiency treatmentwith the classifications of the market based on therapy type, drug type, Disease indication and region. Analysis of past market dynamics from 2016 to 2019 is given in the report, which will help readers to benchmark the past trends with current market scenarios with the key players contribution in it. The report has profiled seven key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques. Report has come up with recommendations for future hot spot in APAC region. New research findings, funding policies for projects and its impact on Lysosomal Acid Lipase (LAL) deficiency market are covered in the report.

Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Segment Analysis

The drug type segment is expected to continue its dominance in the forecast period. In 2019 the segment was valued $xx Mn and is expected to reach $xx Mn in 2027. As Kanuma is the only FDA approved drug for the treatment of LAL-D, its market is expected to grow continuously along with ERT. Lack of other therapies for treatment ofthe disease, provides a huge opportunity for the key players to invest in finding new therapies. Emergence and approval of new treatments will eventually boost the market growth. As the prevalence of this deficiency increases, the need for treatments such as liver transplantation and haematopoietic stem cell therapy will increase, gradually leading the market to grow. The therapy type segment is also expected to rise at a CAGR of xx% in the forecast period. Not only for LAL-D treatment, but the market for therapy segment is anticipated to grow due to other disease complications too. Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market To know about the Research Methodology :- Request Free Sample Report

Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Segmentation

The Global LAL-D market is segmented based on-

Type of therapy

• Liver Transplant • Haematopoietic Stem Cell Transplant

Type of Drug

• Statins and Other Dyslipidemia Drugs • Sebelipasealfa (Kanuma)

Disease indication

• Wolman Disease • Cholesteryl Ester Storage Disease (CESD)

Scope of Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market :Inquire before buying

Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Regional Insights

Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market1 North America is expected to dominate the market in the forecast period owing to the rapid innovations in healthcare domain, drug development and increasing economy. The approval of Alexion’s Kanuma boosted the market growth in this region. Also, presence of top key players is a major reason for the market to elevate. Europe is expected to be the second largest for LAL-D treatment market. European Commission granted permission for marketing of Kanuma for the treatment of LAL-D patients. This is expected to fuel the market growth in this region.

Key players operating the Global LAL-D market

• Alexion Pharmaceuticals Inc • AstraZeneca plc • Merck & Co, Inc • Pfizer, Inc • Teva Pharmaceutical Industries Ltd • Thermo Fisher Scientific • Lonza Group Ltd The objective of the report is to present a comprehensive analysis of the Global Lysosomal Acid Lipase (LAL) deficiency market of all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Lysosomal Acid Lipase (LAL) deficiency market dynamics, structure by analysing the market segments and project the Global Lysosomal Acid Lipase (LAL) deficiency market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Lysosomal Acid Lipase (LAL) deficiency market make the report investor’s guide.

Global Lysosomal Acid Lipase (LAL) Deficiency Treatment Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis and Forecast 6.1. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis and Forecast, By Therapy type 7.1. Introduction and Definition 7.2. Key Findings 7.3. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Therapy type 7.4. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Size (US$ Mn) Forecast, By Therapy type 7.5. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis, By Therapy type 7.6. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Attractiveness Analysis, By Therapy type 8. Global LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis and Forecast, By Drug Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Drug Type 8.4. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Size (US$ Mn) Forecast, By Drug Type 8.5. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis, By Drug Type 8.6. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Attractiveness Analysis, By Drug Type 9. Global LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis and Forecast By Disease indication 9.1. Introduction and Definition 9.2. Key Findings 9.3. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Disease indication 9.4. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Size (US$ Mn) Forecast, By Disease indication 9.5. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis, By Disease indication 9.6. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Attractiveness Analysis, By Disease indication 10. Global LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis, By Region 10.1. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Region 10.2. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Size (US$ Mn) Forecast, By Region 10.3. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Attractiveness Analysis, By Region 11. North America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis 11.1. Key Findings 11.2. North America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Overview 11.3. North America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Therapy type 11.4. North America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 11.4.1. Liver Transplant 11.4.2. Hematopoietic Stem Cell Transplant 11.5. North America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Drug Type 11.6. North America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 11.6.1. Statins and Other Dyslipidemia Drugs 11.6.2. Sebelipasealfa (Kanuma) 11.7. North America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Disease indication 11.8. North America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 11.8.1. Wolman Disease 11.8.2. Cholesteryl Ester Storage Disease (CESD) 11.9. North America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Country 11.10. North America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Country 11.10.1. U.S. 11.10.2. Canada 11.10.3. Mexico 11.11. North America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis, By Country 11.12. U.S. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 11.12.1. Liver Transplant 11.12.2. Hematopoietic Stem Cell Transplant 11.13. U.S. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 11.13.1. Statins and Other Dyslipidemia Drugs 11.13.2. Sebelipasealfa (Kanuma) 11.14. U.S. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 11.14.1. Wolman Disease 11.14.2. Cholesteryl Ester Storage Disease (CESD) 11.15. Canada LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 11.15.1. Liver Transplant 11.15.2. Hematopoietic Stem Cell Transplant 11.16. Canada LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 11.16.1. Statins and Other Dyslipidemia Drugs 11.16.2. Sebelipasealfa (Kanuma) 11.17. Canada LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 11.17.1. Wolman Disease 11.17.2. Cholesteryl Ester Storage Disease (CESD) 11.18. Mexico LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 11.18.1. Liver Transplant 11.18.2. Hematopoietic Stem Cell Transplant 11.19. Mexico LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 11.19.1. Statins and Other Dyslipidemia Drugs 11.19.2. Sebelipasealfa (Kanuma) 11.20. Mexico LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 11.20.1. Wolman Disease 11.20.2. Cholesteryl Ester Storage Disease (CESD) 11.21. North America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Attractiveness Analysis 11.21.1. By Therapy type 11.21.2. By Drug Type 11.21.3. By Disease indication 11.22. PEST Analysis 11.23. Key Trends 11.24. Key Developments 12. Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis 12.1. Key Findings 12.2. Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Overview 12.3. Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Therapy type 12.4. Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 12.4.1. Liver Transplant 12.4.2. Hematopoietic Stem Cell Transplant 12.5. Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Drug Type 12.6. Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 12.6.1. Statins and Other Dyslipidemia Drugs 12.6.2. Sebelipasealfa (Kanuma) 12.7. Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Disease indication 12.8. Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 12.8.1. Wolman Disease 12.8.2. Cholesteryl Ester Storage Disease (CESD) 12.9. Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Country 12.10. Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Sweden 12.10.7. CIS countries 12.10.8. Rest of Europe 12.11. Germany LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 12.11.1. Liver Transplant 12.11.2. Hematopoietic Stem Cell Transplant 12.12. Germany LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 12.12.1. Statins and Other Dyslipidemia Drugs 12.12.2. Sebelipasealfa (Kanuma) 12.13. Germany LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 12.13.1. Wolman Disease 12.13.2. Cholesteryl Ester Storage Disease (CESD) 12.14. U.K. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 12.14.1. Liver Transplant 12.14.2. Hematopoietic Stem Cell Transplant 12.15. U.K. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 12.15.1. Statins and Other Dyslipidemia Drugs 12.15.2. Sebelipasealfa (Kanuma) 12.16. U.K. LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 12.16.1. Wolman Disease 12.16.2. Cholesteryl Ester Storage Disease (CESD) 12.17. France LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 12.17.1. Liver Transplant 12.17.2. Hematopoietic Stem Cell Transplant 12.18. France LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 12.18.1. Statins and Other Dyslipidemia Drugs 12.18.2. Sebelipasealfa (Kanuma) 12.19. France LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 12.19.1. Wolman Disease 12.19.2. Cholesteryl Ester Storage Disease (CESD) 12.20. Italy LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 12.20.1. Liver Transplant 12.20.2. Hematopoietic Stem Cell Transplant 12.21. Italy LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 12.21.1. Statins and Other Dyslipidemia Drugs 12.21.2. Sebelipasealfa (Kanuma) 12.22. Italy LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 12.22.1. Wolman Disease 12.22.2. Cholesteryl Ester Storage Disease (CESD) 12.23. Spain LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 12.23.1. Liver Transplant 12.23.2. Hematopoietic Stem Cell Transplant 12.24. Spain LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 12.24.1. Statins and Other Dyslipidemia Drugs 12.24.2. Sebelipasealfa (Kanuma) 12.25. Spain LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 12.25.1. Wolman Disease 12.25.2. Cholesteryl Ester Storage Disease (CESD) 12.26. Sweden LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 12.26.1. Liver Transplant 12.26.2. Hematopoietic Stem Cell Transplant 12.27. Sweden LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 12.27.1. Statins and Other Dyslipidemia Drugs 12.27.2. Sebelipasealfa (Kanuma) 12.28. Sweden LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 12.28.1. Wolman Disease 12.28.2. Cholesteryl Ester Storage Disease (CESD) 12.29. CIS countries LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 12.29.1. Liver Transplant 12.29.2. Hematopoietic Stem Cell Transplant 12.30. CIS countries LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 12.30.1. Statins and Other Dyslipidemia Drugs 12.30.2. Sebelipasealfa (Kanuma) 12.31. CIS countries LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 12.31.1. Wolman Disease 12.31.2. Cholesteryl Ester Storage Disease (CESD) 12.32. Rest of Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 12.32.1. Liver Transplant 12.32.2. Hematopoietic Stem Cell Transplant 12.33. Rest of Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 12.33.1. Statins and Other Dyslipidemia Drugs 12.33.2. Sebelipasealfa (Kanuma) 12.34. Rest of Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 12.34.1. Wolman Disease 12.34.2. Cholesteryl Ester Storage Disease (CESD) 12.35. Europe LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Attractiveness Analysis 12.35.1. By Drug Type 12.35.2. By Therapy type 12.35.3. By Disease indication 12.36. PEST Analysis 12.37. Key Trends 12.38. Key Developments 13. Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis 13.1. Key Findings 13.2. Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Overview 13.3. Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Therapy type 13.4. Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 13.4.1. Liver Transplant 13.4.2. Hematopoietic Stem Cell Transplant 13.5. Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Drug Type 13.6. Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 13.6.1. Statins and Other Dyslipidemia Drugs 13.6.2. Sebelipasealfa (Kanuma) 13.7. Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Disease indication 13.8. Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 13.8.1. Wolman Disease 13.8.2. Cholesteryl Ester Storage Disease (CESD) 13.9. Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Country 13.10. Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. ASEAN 13.10.7. Rest of Asia Pacific 13.11. Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis, By Country 13.12. China LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 13.12.1. Liver Transplant 13.12.2. Hematopoietic Stem Cell Transplant 13.13. China LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 13.13.1. Statins and Other Dyslipidemia Drugs 13.13.2. Sebelipasealfa (Kanuma) 13.14. China LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 13.14.1. Wolman Disease 13.14.2. Cholesteryl Ester Storage Disease (CESD) 13.15. India LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 13.15.1. Liver Transplant 13.15.2. Hematopoietic Stem Cell Transplant 13.16. India LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 13.16.1. Statins and Other Dyslipidemia Drugs 13.16.2. Sebelipasealfa (Kanuma) 13.17. India LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 13.17.1. Wolman Disease 13.17.2. Cholesteryl Ester Storage Disease (CESD) 13.18. Japan LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 13.18.1. Liver Transplant 13.18.2. Hematopoietic Stem Cell Transplant 13.19. Japan LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 13.19.1. Statins and Other Dyslipidemia Drugs 13.19.2. Sebelipasealfa (Kanuma) 13.20. Japan LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 13.20.1. Wolman Disease 13.20.2. Cholesteryl Ester Storage Disease (CESD) 13.21. South Korea LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 13.21.1. Liver Transplant 13.21.2. Hematopoietic Stem Cell Transplant 13.22. South Korea LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 13.22.1. Statins and Other Dyslipidemia Drugs 13.22.2. Sebelipasealfa (Kanuma) 13.23. South Korea LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 13.23.1. Wolman Disease 13.23.2. Cholesteryl Ester Storage Disease (CESD) 13.24. Australia LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 13.24.1. Liver Transplant 13.24.2. Hematopoietic Stem Cell Transplant 13.25. Australia LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 13.25.1. Statins and Other Dyslipidemia Drugs 13.25.2. Sebelipasealfa (Kanuma) 13.26. Australia LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 13.26.1. Wolman Disease 13.26.2. Cholesteryl Ester Storage Disease (CESD) 13.27. ASEAN LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 13.27.1. Liver Transplant 13.27.2. Hematopoietic Stem Cell Transplant 13.28. ASEAN LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 13.28.1. Statins and Other Dyslipidemia Drugs 13.28.2. Sebelipasealfa (Kanuma) 13.29. ASEAN LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 13.29.1. Wolman Disease 13.29.2. Cholesteryl Ester Storage Disease (CESD) 13.30. Rest of Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 13.30.1. Liver Transplant 13.30.2. Hematopoietic Stem Cell Transplant 13.31. Rest of Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 13.31.1. Statins and Other Dyslipidemia Drugs 13.31.2. Sebelipasealfa (Kanuma) 13.32. Rest of Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 13.32.1. Wolman Disease 13.32.2. Cholesteryl Ester Storage Disease (CESD) 13.33. Asia Pacific LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Attractiveness Analysis 13.33.1. By Therapy type 13.33.2. By Drug Type 13.33.3. By Disease indication 13.34. PEST Analysis 13.35. Key Trends 13.36. Key Developments 14. Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis 14.1. Key Findings 14.2. Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Overview 14.3. Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Therapy type 14.4. Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 14.4.1. Liver Transplant 14.4.2. Hematopoietic Stem Cell Transplant 14.5. Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Drug Type 14.6. Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 14.6.1. Statins and Other Dyslipidemia Drugs 14.6.2. Sebelipasealfa (Kanuma) 14.7. Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Disease indication 14.8. Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 14.8.1. Wolman Disease 14.8.2. Cholesteryl Ester Storage Disease (CESD) 14.9. Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Country 14.10. Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Country 14.10.1. GCC Countries 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.10.5. Rest of Middle East & Africa 14.11. Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis, By Country 14.12. GCC Countries LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 14.12.1. Liver Transplant 14.12.2. Hematopoietic Stem Cell Transplant 14.13. GCC Countries LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 14.13.1. Statins and Other Dyslipidemia Drugs 14.13.2. Sebelipasealfa (Kanuma) 14.14. GCC Countries LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 14.14.1. Wolman Disease 14.14.2. Cholesteryl Ester Storage Disease (CESD) 14.15. South Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 14.15.1. Liver Transplant 14.15.2. Hematopoietic Stem Cell Transplant 14.16. South Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 14.16.1. Statins and Other Dyslipidemia Drugs 14.16.2. Sebelipasealfa (Kanuma) 14.17. South Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 14.17.1. Wolman Disease 14.17.2. Cholesteryl Ester Storage Disease (CESD) 14.18. Nigeria LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 14.18.1. Liver Transplant 14.18.2. Hematopoietic Stem Cell Transplant 14.19. Nigeria LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 14.19.1. Statins and Other Dyslipidemia Drugs 14.19.2. Sebelipasealfa (Kanuma) 14.20. Nigeria LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 14.20.1. Wolman Disease 14.20.2. Cholesteryl Ester Storage Disease (CESD) 14.21. Egypt LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 14.21.1. Liver Transplant 14.21.2. Hematopoietic Stem Cell Transplant 14.22. Egypt LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 14.22.1. Statins and Other Dyslipidemia Drugs 14.22.2. Sebelipasealfa (Kanuma) 14.23. Egypt LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 14.23.1. Wolman Disease 14.23.2. Cholesteryl Ester Storage Disease (CESD) 14.24. Rest of Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 14.24.1. Liver Transplant 14.24.2. Hematopoietic Stem Cell Transplant 14.25. Rest of Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 14.25.1. Statins and Other Dyslipidemia Drugs 14.25.2. Sebelipasealfa (Kanuma) 14.26. Rest of Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 14.26.1. Wolman Disease 14.26.2. Cholesteryl Ester Storage Disease (CESD) 14.27. Middle East & Africa LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Attractiveness Analysis 14.27.1. By Therapy type 14.27.2. By Drug Type 14.27.3. By Disease indication 14.28. PEST Analysis 14.29. Key Trends 14.30. Key Developments 15. South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis 15.1. Key Findings 15.2. South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Overview 15.3. South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Therapy type 15.4. South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 15.4.1. Liver Transplant 15.4.2. Hematopoietic Stem Cell Transplant 15.5. South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Drug Type 15.6. South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 15.6.1. Statins and Other Dyslipidemia Drugs 15.6.2. Sebelipasealfa (Kanuma) 15.7. South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Disease indication 15.8. South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 15.8.1. Wolman Disease 15.8.2. Cholesteryl Ester Storage Disease (CESD) 15.9. South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Value Share Analysis, By Country 15.10. South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Country 15.10.1. Brazil 15.10.2. Colombia 15.10.3. Argentina 15.10.4. Rest of South America 15.11. South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Analysis, By Country 15.12. Brazil LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 15.12.1. Liver Transplant 15.12.2. Hematopoietic Stem Cell Transplant 15.13. Brazil LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 15.13.1. Statins and Other Dyslipidemia Drugs 15.13.2. Sebelipasealfa (Kanuma) 15.14. Brazil LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 15.14.1. Wolman Disease 15.14.2. Cholesteryl Ester Storage Disease (CESD) 15.15. Colombia LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 15.15.1. Liver Transplant 15.15.2. Hematopoietic Stem Cell Transplant 15.16. Colombia LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 15.16.1. Statins and Other Dyslipidemia Drugs 15.16.2. Sebelipasealfa (Kanuma) 15.17. Colombia LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 15.17.1. Wolman Disease 15.17.2. Cholesteryl Ester Storage Disease (CESD) 15.18. Argentina LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 15.18.1. Liver Transplant 15.18.2. Hematopoietic Stem Cell Transplant 15.19. Argentina LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 15.19.1. Statins and Other Dyslipidemia Drugs 15.19.2. Sebelipasealfa (Kanuma) 15.20. Argentina LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 15.20.1. Wolman Disease 15.20.2. Cholesteryl Ester Storage Disease (CESD) 15.21. Rest of South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Therapy type 15.21.1. Liver Transplant 15.21.2. Hematopoietic Stem Cell Transplant 15.22. Rest of South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Drug Type 15.22.1. Statins and Other Dyslipidemia Drugs 15.22.2. Sebelipasealfa (Kanuma) 15.23. Rest of South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Forecast, By Disease indication 15.23.1. Wolman Disease 15.23.2. Cholesteryl Ester Storage Disease (CESD) 15.24. South America LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY Market Attractiveness Analysis 15.24.1. By Therapy type 15.24.2. By Drug Type 15.24.3. By Disease indication 15.25. PEST Analysis 15.26. Key Trends 15.27. Key Developments 16. Company Profiles 16.1. Market Share Analysis, By Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players By price, presence, market share, Drug Type, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A By Regions, Investment and Drug Type 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Alexion Pharmaceuticals Inc 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. AstraZeneca plc 16.3.3. Merck & Co, Inc 16.3.4. Pfizer, Inc 16.3.5. Teva Pharmaceutical Industries Ltd 16.3.6. Thermo Fisher Scientific 16.3.7. Lonza Group Ltd

About This Report

Report ID 82146
Category Healthcare
Published Date Feb 2021
Updated Date
Contact Us